LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | PF431396 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1271 | 4513 | 0.2817 | 0.0109 |
MDA-MB-231 | PF477736 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1498 | 4513 | 0.3320 | 0.0802 |
MDA-MB-231 | PF562271 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1258 | 4513 | 0.2787 | 0.0067 |
MDA-MB-231 | PHA-665752 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4343 | 4513 | 0.9623 | 0.9481 |
MDA-MB-231 | PHA-793887 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 690 | 4513 | 0.1529 | -0.1665 |
MDA-MB-231 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1612 | 4513 | 0.3571 | 0.1147 |
MDA-MB-231 | PLX-4720 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4064 | 4513 | 0.9004 | 0.8628 |
MDA-MB-231 | QL-X-138 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2125 | 4513 | 0.4708 | 0.2712 |
MDA-MB-231 | QL-XII-47 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 997 | 4513 | 0.2209 | -0.0729 |
MDA-MB-231 | Radicicol | 3.33 | uM | LJP5 | 72 | hr | 1235 | 916 | 4513 | 0.2031 | -0.0974 |
MDA-MB-231 | Radicicol | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1072 | 4513 | 0.2375 | -0.0500 |
MDA-MB-231 | Seliciclib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 3754 | 4513 | 0.8319 | 0.7684 |
MDA-MB-231 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4242 | 4513 | 0.9398 | 0.9171 |
MDA-MB-231 | XL147 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4806 | 4513 | 1.0648 | 1.0892 |
MDA-MB-231 | Saracatinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2626 | 4513 | 0.5819 | 0.4243 |
MDA-MB-231 | Selumetinib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 2332 | 4513 | 0.5167 | 0.3344 |
MDA-MB-231 | Sirolimus | 3.33 | uM | LJP6 | 72 | hr | 1235 | 3311 | 4513 | 0.7336 | 0.6332 |
MDA-MB-231 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4497 | 4513 | 0.9965 | 0.9951 |
MDA-MB-231 | SU11274 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 3672 | 4513 | 0.8137 | 0.7434 |
MDA-MB-231 | Fedratinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1103 | 4513 | 0.2444 | -0.0406 |
MDA-MB-231 | TGX221 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 4251 | 4513 | 0.9420 | 0.9201 |
MDA-MB-231 | Torin1 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 1409 | 4513 | 0.3122 | 0.0529 |
MDA-MB-231 | Torin2 | 3.33 | uM | LJP5 | 72 | hr | 1235 | 428 | 4513 | 0.0948 | -0.2465 |
MDA-MB-231 | Tozasertib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1421 | 4513 | 0.3148 | 0.0565 |
MDA-MB-231 | Trametinib | 3.33 | uM | LJP5 | 72 | hr | 1235 | 1275 | 4513 | 0.2826 | 0.0121 |